Click on a filter below to refine your search. Remove a filter to broaden your search.
Metformin displayed a lowest risk for dementia across diverse antidiabetics, while α-glucosidase inhibitors had the highest risk.
No significant increase was seen with the use of GLP-1 RAs versus SGLT2is or DPP4is among older Medicare beneficiaries.
R&D has remained relatively stable among large pharma companies despite a 27.3% growth in sales.
The trial results could be out by September and may lead to the FDA emergency use authorization.
ChatGPT deprescribing decisions varied along activities of daily living status, cardiovascular disease history, and medication type
Supply disruptions increased for drugs with and without reports at the start of the COVID-19 pandemic.
The agency, however, noted that officials cannot rule out that “a small risk may exist,” and said it will continue to investigate.
Polypharmacy increased, peaking at 43.0% in 2017 to March 2020; hyperpolypharmacy increased during 1999-2000 to 2007-2008.
Few older adults with mild cognitive impairment or mild dementia were eligible for lecanemab or aducanumab after applying clinical trial criteria.
No association was seen for rebound symptoms or test positivity with symptoms of long COVID.